<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00450736</url>
  </required_header>
  <id_info>
    <org_study_id>20030283</org_study_id>
    <secondary_id>SCCC-2003053</secondary_id>
    <secondary_id>WIRB-20051240</secondary_id>
    <nct_id>NCT00450736</nct_id>
  </id_info>
  <brief_title>Celecoxib and Radiation Therapy in Treating Patients With Stage II or Stage III Soft Tissue Sarcoma of the Arm, Hand, Leg, or Foot That Has Been Removed by Surgery</brief_title>
  <official_title>A Phase I Trial of Postoperative Radiation With Dose-Escalation of A Cox-2 Inhibitor, Celebrex™ (CELECOXIB) in Patients With Soft Tissue Sarcoma of the Extremity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Miami</source>
  <brief_summary>
    <textblock>
      RATIONALE: Celecoxib may stop the growth of tumor cells by blocking some of the enzymes&#xD;
      needed for cell growth and by blocking blood flow to the tumor. Radiation therapy uses&#xD;
      high-energy x-rays to kill tumor cells. Giving celecoxib together with radiation therapy&#xD;
      after surgery may kill any tumor cells that remain after surgery.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of celecoxib when&#xD;
      given together with radiation therapy in treating patients with stage II or stage III soft&#xD;
      tissue sarcoma of the arm, hand, leg, or foot that has been removed by surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the maximum tolerated dose of adjuvant celecoxib administered with&#xD;
           radiotherapy in patients with resected stage II or III soft tissue sarcoma of the&#xD;
           extremity.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of celecoxib.&#xD;
&#xD;
      Beginning within 10 weeks of the most recent resection, patients undergo standard&#xD;
      radiotherapy once daily, 5 days a week, in weeks 1-7. Patients also receive oral celecoxib&#xD;
      twice daily in weeks 1-7 in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of celecoxib until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2&#xD;
      of 6 patients experience dose-limiting toxicity. A maximum of 6 patients are treated at the&#xD;
      MTD.&#xD;
&#xD;
      After completion of study treatment, patients are followed periodically.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 24 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2004</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Local failure</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Regional relapse</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distant failure</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Childhood Malignant Fibrous Histiocytoma of Bone</condition>
  <condition>Sarcoma</condition>
  <arm_group>
    <arm_group_label>Single Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>celecoxib</intervention_name>
    <arm_group_label>Single Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
    <arm_group_label>Single Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <arm_group_label>Single Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed soft tissue sarcoma of the extremity, including the following&#xD;
             disease types:&#xD;
&#xD;
               -  Liposarcoma&#xD;
&#xD;
               -  Leiomyosarcoma&#xD;
&#xD;
               -  Synovial cell sarcoma&#xD;
&#xD;
               -  Malignant fibrous histiocytoma&#xD;
&#xD;
               -  Spindle cell sarcoma&#xD;
&#xD;
               -  Fibrosarcoma&#xD;
&#xD;
               -  Chondrosarcoma&#xD;
&#xD;
               -  Angiosarcoma&#xD;
&#xD;
               -  Hemangiopericytoma&#xD;
&#xD;
               -  Neurofibrosarcoma&#xD;
&#xD;
          -  The following disease types are excluded:&#xD;
&#xD;
               -  Kaposi's sarcoma&#xD;
&#xD;
               -  Rhabdomyosarcoma&#xD;
&#xD;
               -  Dermatofibrosarcoma&#xD;
&#xD;
               -  Epithelioid cell sarcoma&#xD;
&#xD;
               -  Ewing's sarcoma&#xD;
&#xD;
               -  Osteosarcoma&#xD;
&#xD;
          -  Intermediate- or high-grade tumor ≥ 5.0 cm in 1 dimension (stage II or III disease)&#xD;
&#xD;
          -  Locally resected disease&#xD;
&#xD;
               -  One prior wide local excision of the sarcoma in the same location of the&#xD;
                  extremity within the past 6 months allowed&#xD;
&#xD;
               -  Prior neoadjuvant chemotherapy (of ≤ 3 courses), followed by a limb-sparing&#xD;
                  surgical resection of sarcoma found to have &lt; 90% pathological tumor necrosis&#xD;
                  allowed&#xD;
&#xD;
               -  Prior resection of an extremity mass that is subsequently found to be a sarcoma&#xD;
                  meeting study criteria, followed by ≤ 3 courses of chemotherapy (independent of&#xD;
                  the percentage of pathological tumor necrosis) allowed&#xD;
&#xD;
          -  No evidence of nodal or distant metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Karnofsky performance status 70-100%&#xD;
&#xD;
          -  WBC ≥ 3,000/mm³&#xD;
&#xD;
          -  Absolute granulocyte count ≥ 1,500/mm³&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm³&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 mg/dL&#xD;
&#xD;
          -  SGPT and SGOT ≤ 2.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Creatinine ≤ 1.5 times ULN&#xD;
&#xD;
          -  Calcium ≤ 1.3 times ULN&#xD;
&#xD;
          -  No prior malignancy except cutaneous nonmelanomatous skin cancer, carcinoma in situ of&#xD;
             the cervix, or other cancer for which the patient has been disease-free for at least 5&#xD;
             years&#xD;
&#xD;
          -  No history of allergic reaction to sulfonamides or NSAIDs&#xD;
&#xD;
          -  No known hypersensitivity to celecoxib or any component of its formulation&#xD;
&#xD;
          -  No known HIV positivity&#xD;
&#xD;
          -  No known coronary artery disease&#xD;
&#xD;
          -  No cardiac event of any kind within the past 6 months&#xD;
&#xD;
          -  No concurrent unstable cardiac status&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior radiotherapy to the extremity requiring radiation for this study&#xD;
&#xD;
          -  No prior systemic chemotherapy for a malignant tumor&#xD;
&#xD;
          -  No concurrent dilantin or lithium carbonate&#xD;
&#xD;
          -  No other concurrent prescription or over-the-counter nonsteroidal anti-inflammatory&#xD;
             agents (NSAIDs)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aaron H. Wolfson, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Miami Sylvester Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Miami Sylvester Comprehensive Cancer Center - Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <study_first_submitted>March 20, 2007</study_first_submitted>
  <study_first_submitted_qc>March 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2007</study_first_posted>
  <last_update_submitted>December 14, 2016</last_update_submitted>
  <last_update_submitted_qc>December 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>chondrosarcoma</keyword>
  <keyword>adult angiosarcoma</keyword>
  <keyword>adult fibrosarcoma</keyword>
  <keyword>adult leiomyosarcoma</keyword>
  <keyword>adult liposarcoma</keyword>
  <keyword>adult neurofibrosarcoma</keyword>
  <keyword>adult synovial sarcoma</keyword>
  <keyword>childhood angiosarcoma</keyword>
  <keyword>childhood fibrosarcoma</keyword>
  <keyword>childhood leiomyosarcoma</keyword>
  <keyword>childhood liposarcoma</keyword>
  <keyword>childhood neurofibrosarcoma</keyword>
  <keyword>childhood synovial sarcoma</keyword>
  <keyword>nonmetastatic childhood soft tissue sarcoma</keyword>
  <keyword>stage II adult soft tissue sarcoma</keyword>
  <keyword>stage III adult soft tissue sarcoma</keyword>
  <keyword>adult malignant fibrous histiocytoma</keyword>
  <keyword>adult malignant hemangiopericytoma</keyword>
  <keyword>childhood malignant hemangiopericytoma</keyword>
  <keyword>localized childhood malignant fibrous histiocytoma of bone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Histiocytoma</mesh_term>
    <mesh_term>Histiocytoma, Benign Fibrous</mesh_term>
    <mesh_term>Histiocytoma, Malignant Fibrous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

